The choice of test in phase II cancer trials assessing continuous tumour shrinkage when complete responses are expected
Traditionally, phase II cancer trials test a binary endpoint formed from a dichotomisation of the continuous change in tumour size. Directly testing the continuous endpoint provides considerable gains in power, although also results in several statistical issues. One such issue is when complete resp...
| Main Authors: | , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
SAGE Publications
2015
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4668774/ |